RESUMO
AIMS: We evaluated if type 1 diabetic patients have altered levels of low-grade inflammatory markers including platelet-activating factor acetylhydrolase (PAF-AH) activity, high-sensitivity C-reactive protein (hs-CRP), white blood cells count (WBC), erythrocyte sedimentation rate (ESR) and LDL-cholesterol oxidation coefficient (OxC), and whether their levels are related to clinical complications and the metabolic profile. METHODS: We studied cross-sectionally 118 outpatients with type 1 diabetes both with (n=38) and without (n=80) clinical chronic complications, and 110 controls subjects. RESULTS: Diabetic patients had higher levels of PAF-AH activity (p=0.02), hs-CRP (p=0.001), WBC (p=0.004) and ESR (p=0.0001) than controls. Patients with type 1 diabetes had earlier OxC than the non-diabetic subjects at 1 and 3 h (p=0.01) after the addition of CuSO(4). No difference was noted between patients with and without chronic complications. In the patients, correlations were found between PAF-AH activity and OxC at 1 and 3 h. CONCLUSIONS: It was concluded that the susceptibility of LDL to in vitro oxidation and low-grade inflammation are increased in patients with type 1 diabetes and related to each other. The presence of these markers is probably independent of the presence of chronic clinical complications and reveals the development of early pro-inflammatory state.
Assuntos
1-Alquil-2-acetilglicerofosfocolina Esterase/sangue , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/enzimologia , Inflamação/sangue , Adolescente , Adulto , Biomarcadores/sangue , Proteína C-Reativa/metabolismo , LDL-Colesterol/sangue , Estudos Transversais , Feminino , Humanos , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Pacientes Ambulatoriais , Oxirredução , Valores de Referência , Inquéritos e Questionários , Adulto JovemRESUMO
Plasma activity of the platelet-activating factor acetylhydrolase (PAF-AH) plays an important role in inflammation and atherosclerotic process in chronic diseases. We aimed to evaluate the levels of PAF-AH activity and their association with the metabolic profile and chronic complications in patients with type 1 diabetes. The study included 118 outpatients (54 males) aged 27.1+/-11.3 years with disease duration of 12.3+/-8.5 years with (n=38) or without (n=80) diabetes complications and 96 control subjects (48 males) matched for age, gender, body mass index and smoking habits. The serum levels of PAF-AH activity were higher in patients either with or without chronic complications (16+/-5.3 and 14+/-5.4 nmol/(min mL), respectively) than in controls (13+/-5.1 nmol/(min mL), P=0.02). In the total population, PAF-AH activity was correlated with age, HDL-cholesterol, total cholesterol and LDL-cholesterol. In patients, PAF-AH activity was correlated with age, HbA1c, uric acid, HDL-cholesterol, cholesterol, LDL-cholesterol, cholesterol/HDL-cholesterol ratio and the LDL-cholesterol/HDL-cholesterol ratio. It is concluded that PAF-AH plasma activity could be a novel candidate for low-grade inflammatory marker in patients with type 1 diabetes.